Methylphenidate (MP), a widely used medicine for attention deficit/hyperactivity disorder (ADHD), is commonly prescribed in combination with selective serotonin reuptake inhibitors (SSRI) e.g., fluoxetine (FLX). However, neurochemical effects of the MP + FLX combination have not been sufficiently elucidated. Given the pivotal role played by glutamatergic signaling in psychostimulant responses and corticostriatal plasticity, we employed a 2-level factorial design to assess how the individual…
